Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

23Andme Holding Co. (ME)

23Andme Holding Co. (ME)
3.52 -0.06 (-1.68%) 10:04 ET [NASDAQ]
3.49 x 600 3.53 x 800
Realtime by (Cboe BZX)
3.49 x 600 3.53 x 800
Realtime 3.69 +0.11 (+3.07%) 08:06 ET
Quote Overview for Wed, Jan 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.49
Day High
3.60
Open 3.60
Previous Close 3.58 3.58
Volume 12,176 12,176
Avg Vol 209,046 209,046
Stochastic %K 41.14% 41.14%
Weighted Alpha -69.37 -69.37
5-Day Change +0.10 (+2.95%) +0.10 (+2.95%)
52-Week Range 2.65 - 16.52 2.65 - 16.52
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 93,502
  • Shares Outstanding, K 26,118
  • Annual Sales, $ 219,640 K
  • Annual Income, $ -666,700 K
  • EBIT $ -274 M
  • EBITDA $ 107 M
  • 60-Month Beta 1.14
  • Price/Sales 0.43
  • Price/Cash Flow 1.22
  • Price/Book 0.92

Options Overview Details

View History
  • Implied Volatility 104.56% ( +7.31%)
  • Historical Volatility 72.85%
  • IV Percentile 14%
  • IV Rank 10.25%
  • IV High 595.39% on 08/05/24
  • IV Low 48.48% on 04/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 14
  • Volume Avg (30-Day) 284
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 7,975
  • Open Int (30-Day) 40,912

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.06 +14.05%
on 12/26/24
Period Open: 3.27
4.18 -16.51%
on 01/08/25
+0.22 (+6.73%)
since 12/20/24
3-Month
2.65 +31.45%
on 11/19/24
Period Open: 4.85
5.35 -34.74%
on 11/12/24
-1.36 (-28.04%)
since 10/22/24
52-Week
2.65 +31.45%
on 11/19/24
Period Open: 14.45
16.52 -78.87%
on 02/16/24
-10.96 (-75.84%)
since 01/22/24

Most Recent Stories

More News
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology

ME : 3.52 (-1.68%)
Want $500 of Reliable Dividend Income in 2025? Invest $5,040 in These 3 Ultra-High-Yield Stocks.

It's been a great couple of years for investors holding U.S. equities. From the end of 2022 through Dec. 27, the benchmark S&P 500 index soared 55.5%.

ME : 3.52 (-1.68%)
HTGC : 20.90 (+0.24%)
PFLT : 11.31 (+0.09%)
ARCC : 23.30 (-0.30%)
PLTR : 74.31 (+1.70%)
The Shake-Up at Intel

And cybersecurity consultant Dave Hatter helps us see what's really going on with all of our information.

META : 628.63 (+1.97%)
GOOGL : 199.22 (+0.59%)
NVDA : 146.50 (+4.03%)
GOOG : 200.87 (+0.62%)
AAPL : 222.70 (+0.03%)
AKAM : 94.08 (-0.67%)
ASML : 782.45 (+2.55%)
TSM : 222.95 (+1.94%)
MSFT : 440.65 (+2.84%)
INTC : 22.11 (+1.56%)
AMD : 124.24 (+1.60%)
ME : 3.52 (-1.68%)
23andMe and Mirador Therapeutics Forge Strategic Research Collaboration to Advance Precision Medicine in Immunology and Inflammation

23andMe and Mirador Therapeutics announce a collaboration to enhance precision medicine for immunology and inflammation diseases using genetic data.Quiver AI Summary23andMe Holding Co. and Mirador Therapeutics...

ME : 3.52 (-1.68%)
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation

ME : 3.52 (-1.68%)
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

ME : 3.52 (-1.68%)
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future

ME : 3.52 (-1.68%)
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

ME : 3.52 (-1.68%)
23andMe to Report Q2 FY2025 Financial Results

ME : 3.52 (-1.68%)
23andMe Regains Compliance With Nasdaq Listing Requirements

ME : 3.52 (-1.68%)

Business Summary

23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition...

See More

Key Turning Points

3rd Resistance Point 3.94
2nd Resistance Point 3.83
1st Resistance Point 3.70
Last Price 3.52
1st Support Level 3.46
2nd Support Level 3.35
3rd Support Level 3.22

See More

52-Week High 16.52
Fibonacci 61.8% 11.22
Fibonacci 50% 9.59
Fibonacci 38.2% 7.95
Last Price 3.52
52-Week Low 2.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Master Swing Trading: Strategies for Momentum and Trends